mohitt - Tumblr blog

mohitt · 5 years ago

Text

Bacterial Pneumonia Treatment Market Growth Trends, Current Demand, and Development Report

Global Bacterial Pneumonia Treatment Market: Overview

· Bacterial pneumonia is an inflammation of the lungs due to bacterial infection. Pneumonia is a common lung infection where the lung’s air sacks become inflamed. Different types of bacteria can cause pneumonia, but Streptococcus pneumonia and Haemophilus influenza are primarily responsible for most of the bacterial pneumonia. Common indications of bacterial pneumonia include cough, chest pain, shortness of breath, fever, and chills.

Read Report Overview - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76655

· Bacterial pneumonia is caused by bacteria that works its way into the lungs and then multiplies. It can occur on its own or develop after another illness, like a cold or flu. It can enter the lungs through inhalation or through bloodstream. According to the Cleveland Clinics, people who have a weakened immune system as a result of cancer or organ transplant face an increased risk of bacterial pneumonia.

· The global bacterial pneumonia treatment market is projected to grow at a significant pace during the forecast period, owing to increase in the rate of incidence of bacterial pneumonia across the globe and continuous R&D activities for the development of vaccines and new drugs for bacterial pneumonia.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76655

Key Drivers of Global Bacterial Pneumonia Treatment Market

· Antibiotics are becoming ineffective against bacterial pneumonia due to increase in resistance of bacteria. Innovations are underway in the pharmaceutical industry in the area of new type of antibiotics candidates. This is expected to increase the rate of cure of bacterial pneumonia in the near future.

· Nabriva Therapeutics AG is a biotechnology company involved in the development of pleuromutilins, a new class of antibiotics to treat community-acquired bacterial pneumonia (CABP)

· The continuing need of reinventing the drug pipeline, led by bacterial mutation and resistance, presents an opportunity in the global bacterial pneumonia treatment market

Restraints of Global Bacterial Pneumonia Treatment Market

· Pathways to the approval for bacterial pneumonia drugs from regulatory bodies have become confusing, generally infeasible, and questionably irrelevant to patients and providers over a period of time. Additionally, scientific and regulatory challenges significantly increase the cost of and time required for drug development, which worsens economic disadvantages of bacterial pneumonia drugs.

· In view of the urgency of bacterial drug resistance and the capacity of targeted disease to change rapidly over time, regulatory bodies are not in favor of revision and streamlining of the anti-bacterial drug development and approval process

Request for Analysis of COVID-19 Impact on Bacterial Pneumonia Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=76655

North America to Account for Major Share of Global Bacterial Pneumonia Treatment Market

· North America is likely to dominate the global bacterial pneumonia treatment market during the forecast period, due to high rate of incidence of bacterial pneumonia and high awareness about and adoption of new drugs and treatment methods in the region. According to the American Lung Association, Streptococcus pneumonia germ infects over 900,000 people in the U.S. every year.

· The bacterial pneumonia treatment market in Asia Pacific is expected to expand at a significant CAGR during the forecast period, owing to rise in the incident rate of pneumonia in countries such as India. According to the World Health Organization (WHO), one in three deaths in India is caused by pneumonia. Pneumonia in India is the leading cause of infant deaths. Every year around 200,000 children aged under five succumb to pneumonia in India.

Pre Book Bacterial Pneumonia Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=76655&ltype=S

Key Players Operating in Global Bacterial Pneumonia Treatment Market

Major players operating in the global bacterial pneumonia treatment market are:

· Pfizer, Inc.

· Teva Pharmaceutical Industries, Ltd.

· Lupin Pharmaceuticals, Inc.

· Mylan N.V.

· Sun Pharmaceutical Industries Ltd.

· GlaxoSmithKline plc

· Sanofi

· AstraZeneca plc

· Nabriva Therapeutics plc

· Others

More Trending Reports by Transparency Market Research –

Medical Imaging Information System Market: https://www.biospace.com/article/medical-imaging-information-system-market-increasing-awareness-among-customers-to-support-market-demand-/

Alpha Mannosidosis Market: https://www.prnewswire.co.uk/news-releases/alpha-mannosidosis-market-to-showcase-9-9-cagr-during-2019-2027-and-reach-us-18-7-mn-valuation-by-2027-says-tmr-811882644.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Pneumonia Drugs & Vaccines Market Growth Trends, Current Demand, and Development Report

Pneumonia is a common lung infection caused by a variety of microorganisms such as bacteria, virus, fungi and parasites. In pneumonia the air sacs of lungs that are known as alveoli are filled with fluid or pus causing inflammation. The common symptoms of pneumonia are cough with phlegm, sneezing, sore throat, chills, fever and trouble in breathing.

Read Report Overview - https://www.transparencymarketresearch.com/pneumonia-drugs-vaccines-market.html

Pneumonia is usually a mild disease but under certain situations can be lethal. Children, elderly people and those with recent viral infections, lung disease and heart disease are at higher risk of developing pneumonia compared to general population.

Pneumonia is of different types depending on the way it has been acquired by people such community acquired pneumonia (CAP), hospital acquired pneumonia (HAP) and healthcare associated pneumonia as patient may also develop pneumonia during their visits to other healthcare setting such as nursing homes, dialysis centers and outpatient clinics. Others are aspiration pneumonia and atypical pneumonia. Pneumonia is one of the most common hospital acquired infection.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1735

The global market for pneumonia is segmented broadly into treatment drugs and prevention vaccines market. Usually antibiotics used to treat pneumonia include cephalosporins, penicillin, tetracyclines, fluoroquinolones, amoxicillin, clavulanic acid and vancomycin.

Earlier, penicillin was widely used to treat pneumonia caused by bacteria pnemococcal pneumonia but due to wide spread use of broad spectrum antibiotics has resulted into significant drug resistance. Penicillin is still used but only after confirming the sensitivity of the bacteria towards this antibiotic.

Request for Analysis of COVID-19 Impact on Pneumonia Drugs & Vaccines Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1735

Pneumococcal conjugate vaccine such as PCV13 and pneumococcal polysaccharide vaccines such as PPV23 and Pneumovax are used to prevent pneumococcal diseases. The major players operating in this market are Sanofi, Eli Lilly, AstraZeneca, Merck & Co. Novartis, GlaxoSmithCline, Pfizer and Baxter International Inc.

The market for pneumonia drugs and vaccines is expected to grow under the impact of drivers such as increasing aging population as aging population are more susceptible to developing pneumonia and increasing prevalence of pneumonia among children.

Pre Book Pneumonia Drugs & Vaccines Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1735&ltype=S

According to WHO, every year approximately 1.2 million children under the age of five years die because of pneumonia. WHO also reports only 30% of children suffering from pneumonia get required antibiotics for the treatment of pneumonia. This disease is most prevalent in South Asia and African countries.

More Trending Reports by Transparency Market Research –

Liquid Biopsy Market: https://www.biospace.com/article/liquid-biopsy-market-free-nucleic-acid-segment-held-a-major-share-of-the-market/

Dental Imaging Market: https://www.prnewswire.co.uk/news-releases/technological-advancement-in-diagnostic-imaging-techniques-is-likely-to-boost-dental-imaging-market-growth-tmr-858561418.html

About Us

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Pneumonia Diagnostics & Technologies Market In-depth Analysis, Business Strategies, and Growth Rate

Pneumonia is a type of lung infection caused by microorganisms such as bacteria, virus, fungi and parasites. Streptococcus pneumonia is one of the most common causes of pneumonia among children, others are Haemophilus influenzae type b (Hob) and Pneumocystis jiroveci. It is characterized by symptoms such as short breathing, fever, chest pain, nausea and vomiting.

Read Report Overview - https://www.transparencymarketresearch.com/pneumonia-diagnostics-technologies.html

In pneumonia the air sacs of lungs called as alveoli are filled with fluid or pus that causes inflammation. The treatment of pneumonia depends on severity of symptom and types of pathogens. Usually, antibiotics are given to treat pneumonia caused by bacterial infection while to treat pneumonia caused by fungi, antifungals are prescribed.

It is quite difficult to diagnose pneumonia as its clinical symptoms overlap with many other diseases such as the asthama, bronchitis and common cold. In order to confirm pneumonia, a doctor recommends tests including chest X-ray, blood tests, sputum test, CT scan, pleural fluid culture and pulse oximetry test. The market for pneumonia diagnostics and technologies can be estimated on the basis of volume of tests generated at hospitals, diagnostic laboratories, physician’s own clinics and other healthcare settings.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1736

Chest x-ray and CT scan are generally recommended at hospitals for the diagnosis of pneumonia while community healthcare settings usually recommend diagnosis on the basis of symptoms. Some of the key players operating in this market space are Becton Dickinson, Affymetrix, Bio-Rad, Abbott Laboratories, Roche, Thermo Fisher Scientific, bioMeriux, DiaSorin and Novartis Diagnostics. Some of the diagnostic kits available in the market are Directigen S. pneumonia test kit by Becton Dickinson and LCx Chlamydia pneumonia PCR assay kit by Abbott Laboratories.

Request for Analysis of COVID-19 Impact on Pneumonia Diagnostics & Technologies Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1736

The market for pneumonia diagnostics and technologies is projected to grow under the influence of increasing aging population, recent advances in pneumonia diagnostics and high prevalence of pneumonia among children. Rapid increase in aging population in North America, Europe and Japan will be driving the market in these regions as elder people are more susceptible to develop pneumonia compared to general population. As of April 2013, WHO (world health organization) suggests that pneumonia is one of the major factors causing death in children.

Buy Pneumonia Diagnostics & Technologies Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1736&ltype=S

It is estimated that every year approximately 1.2 million children under the age of five years die due to pneumonia. This disease is most prevalent in South Asia and African countries. The recent advancement in pneumonia diagnostics such as the development of nucleic acid detection tests for major pneumonia pathogens and immunochromatographic pneumococcal urinary antigen tests are predicted to drive the market globally.

More Trending Reports by Transparency Market Research –

Atherectomy Devices Market: https://www.biospace.com/article/atherectomy-devices-market-technological-advancements-to-propel-market/

Intracranial Stents Market: https://www.prnewswire.com/news-releases/intracranial-stents-market-to-clock-cagr-of-10-4-during-20182026--new-approaches-in-stroke-management-pivot-advancements-in-self-expanding-stents-says-tmr-301160541.html

About Us

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Systemic Lupus Erythematosus Treatment Market : Latest Innovations, Future Scope and Market Trends

Treat-to-Target Approach Reduces Incidence of Disease Activity

Although healthcare companies in the systemic lupus erythematosus treatment market have made significant advances regarding drug development, certain side effects of these drugs are anticipated to negatively influence market growth. For instance, immunosuppressive drugs are estimated to reach a value of ~US$ 1.5 billion by 2027, and continue to dominate the systemic lupus erythematosus treatment market throughout the forecast period. However, enduring disease activity with recurring flare ups and accumulating toxicity due to glucocorticoids (GC) and immunosuppressive (IS) medications are some of the side effects associated with SLE drugs.

Since SLE is a heterogeneous disease of varying severity, healthcare companies in the systemic lupus erythematosus treatment landscape are beginning to understand that, developing 'one size fits all' immunosuppressive drugs increases the burden of symptoms in patients. This is why, healthcare companies in the systemic lupus erythematosus treatment market are adopting the 'treat-to-target' approach to develop drugs that effectively manage and minimize the incidence of disease activity. Healthcare providers are implementing patient-tailored therapeutic strategies with the introduction of improved biologic agents.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73932

Biologics and Belimumab Stabilize Therapeutic Armamentarium for Stakeholders in Supply Chain

With the help of successful randomized controlled trials (RCTs) and approvals from health commissions, healthcare companies in the systemic lupus erythematosus treatment market are capitalizing on improved formulations of biologic agents. Other drugs such as biologics and B-cell modulators are projected to be the second-highest revenue generating source for manufacturers, with a value of ~US$ 785 million by 2027. Due to the increasing availability of belimumab, healthcare companies are gaining credibility, as this antibody is found to be efficacious in minimizing flare ups and disease activity. Thus, belimumab has helped stakeholders in the SLE supply chain to maintain a stable therapeutic armamentarium in the market.

Healthcare companies in the systemic lupus erythematosus treatment market are increasing their focus on novel biologic agents that target B cells, T cells, and cytokines, for improving the quality of life in patients. The market value share of the intravenous mode of delivery is estimated to grow from ~39% currently to ~44% by 2027 in the systemic lupus erythematosus treatment market. This is well justified, as healthcare providers are increasingly diagnosing patients with belimumab through intravenous formulations.

Request for COVID19 IMPACT ANALYSIS On Systemic Lupus Erythematosus Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73932

Supportive Treatments Help Companies Broaden Revenue Sources

Apart from advancements in drug delivery, healthcare providers in the systemic lupus erythematosus treatment market are offering supportive treatments, since SLE patients are prone to comorbidities. Thus, healthcare companies can supply hospitals and other healthcare providers with vaccinations to prevent common disease problems such as influenza and streptococcus pneumonia. There is also an increasing need for vaccination against the human papilloma virus (HPV) in adult SLE patients.

Maintaining a steady supply chain of calcium and vitamin D supplements can help healthcare companies in the systemic lupus erythematosus treatment market to broaden and increase their bracket for revenue sources. These supplements are highly recommended for patients who are prescribed glucocorticoids, to avoid the risks of GC-induced osteoporosis. Companies should increase research & development to improve bidirectional control of the risk factors associated with cardiovascular diseases (CVD). Doing this will help them understand the disease-related factors associated with the consumption of statins and antihypertensive drugs by CVD patients.

Analysts’ Viewpoint

Analysts of the systemic lupus erythematosus treatment market estimate a promising growth for the market during the forecast period. Healthcare providers should prescribe low-dose aspirin in conjunction with antiphospholipid antibodies (aPL) to reduce cardiovascular events in patients.

However, in many cases, ineffective management of SLE leads to severe drug-induced toxicity and organ deterioration. Thus, healthcare providers are increasing awareness about long-term maintenance therapy with hydroxychloroquine, as this technique has improved the life expectancy of SLE sufferers.

Since belimumab is the only targeted therapy approved by health commissions for the treatment of SLE, healthcare companies should increase their focus on developing new molecular formulations of the antibody.

Buy Now Systemic Lupus Erythematosus Treatment Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=73932&ltype=S

Systemic Lupus Erythematosus Treatment Market: Key Insights

· Systemic Lupus Erythematosus (SLE) is a prototypic multisystem autoimmune disorder with a broad spectrum of clinical presentations, encompassing almost all organs and tissues. It can affect the skin, joints, kidneys, brain, and other organs.

· SLE is more common in women than men, and can occur at any age. However, it appears most often in people between the ages of 15 and 44. The disease affects African Americans and Asians more than people from other races.

· The global systemic lupus erythematosus treatment market was valued at ~US$ 1.7 Bn in 2018.

· The global systemic lupus erythematosus treatment market is projected to grow at a CAGR of ~7%, and reach a valuation of ~US$ 3 Bn by the year 2027.

Systemic Lupus Erythematosus Treatment Market: Drivers

· Increase in number of systemic lupus erythematosus (SLE) patients has resulted in growth of the global systemic lupus erythematosus treatment market. According to The Lupus Foundation of America, approximately 1.5 million people in the U.S. and 5 to 6 million people across the world are affected with various forms of lupus. Systemic lupus erythematosus affects around 70% of all cases of lupus.

· Numerous pipeline products and recent approvals of drugs to treat systemic lupus erythematosus are expected to drive the systemic lupus erythematosus treatment market during the forecast period.

o In 2019, Merck & Co., Inc., a global leader in autoimmune disease treatment, announced its two potential candidates, Atacicept and Evobrutinib, which are in phase II of clinical trials, to treat conditions such as systemic lupus erythematosus and other autoimmune disorders.

o GlaxoSmithKline plc. and AstraZeneca have a long list of pipeline drugs for autoimmune disorders. Both companies have one potential drug molecule, i.e. Belimumab+rituximab and Anifrolumab TULIP, respectively, which are in phase III of clinical trials, to treat the SLE disorder.

Systemic Lupus Erythematosus Treatment Market: Segment Analysis

· In terms of drug, the immunosuppressive drugs segment is the leading segment in the global systemic lupus erythematosus treatment market. This is due to major manufacturers focusing on the launch of new immunosuppressive drugs.

· In addition, immunosuppressive drugs for the treatment of systemic lupus erythematosus disease are available at low cost, easily accessible, and highly efficient.

· The intravenous segment is projected to be a highly attractive segment during the forecast period. Major market players focusing on launching new products in the injection form due to its high onset of action and less drug degradation, which is likely to propel the intravenous segment in the global systemic lupus erythematosus treatment market.

· Retail pharmacies is a highly preferred distribution channel. Increase in the number of retail pharmacy stores across the globe, availability of new products in retail stores, and availability of most of the drugs, i.e. NSAIDS, antimalarial drugs, corticosteroids as OTC drugs in retail stores, are expected to boost the growth of the retail pharmacies segment in the global systemic lupus erythematosus treatment market.

Systemic Lupus Erythematosus Treatment Market: Geographic Overview

· In terms of region, the global systemic lupus erythematosus treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions for the easy understanding of the overall systemic lupus erythematosus treatment market.

· North America dominates the global systemic lupus erythematosus treatment market with the largest share. The market in Asia Pacific is projected to grow at the highest CAGR among all regions, and be the most lucrative regional systemic lupus erythematosus treatment market.

Systemic Lupus Erythematosus Treatment Market: Major Players

· Leading players analyzed in the report on the global systemic lupus erythematosus treatment market include

o GlaxoSmithKline plc

o F. Hoffmann-La Roche Ltd.

o Pfizer, Inc.

o AstraZeneca

o Merck & Co., Inc.

o Bristol-Myers Squibb Company

o Anthera Pharmaceuticals, Inc.

o ImmuPharma PLC

o Aurinia Pharmaceuticals, Inc.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Schizophrenia Drugs Market Report Analysis With Industry Share Insights Shared in Detailed Report

Companies Increase Focus on Second-generation Drugs with Polypharmacology Approach

Several doctors and healthcare providers are adopting the methods of polypharmacology to develop new drugs for mental disorders. These methods are providing better outcomes in patients as compared to single-target drugs in the schizophrenia drugs market.

Likewise, multi-target drugs are emerging as an effective alternative to treat polygenic diseases, including schizophrenia. As such, the second-generation drugs market is estimated to reach ~US$ 11.1 billion by the year 2027; the highest amongst all drug classes in the schizophrenia drugs landscape. These second-generation drugs, i.e. atypical antipsychotics, target a number of aminergic G-protein coupled receptors (GPCRs) to treat complex pathomechanisms of schizophrenia.

Pharmaceutical companies are increasing research & development related to the schizophrenia drugs market to develop drugs that are beyond the dopaminergic hypothesis of schizophrenia and beyond monoamine G protein coupled receptors (GPCRs). They are increasing their production capacities of dopamine antagonists and drugs meant to effectively control the symptoms of schizophrenia and improve patient quality of life. Manufacturers in the schizophrenia drugs market are also turning towards other second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=67820

High-content Single-cell Screenings Serve as a Strategic Alternative

There is the growing need for improved schizophrenia drugs, as psychiatric disorders lead to disorders of the whole body. That is why, healthcare companies are innovating on live cellular function as a model to treat schizophrenia. Manufacturers in the schizophrenia drugs market are using high-content single-cell screenings to develop efficacious compounds for new schizophrenia drugs. This drug 'repurposing' strategy serves as a cost-effective and time-saving alternative for the development of new schizophrenia drugs that can be supplied to small-scale clinics and other healthcare providers.

The live cellular function model helps manufacturers develop new potential drugs at competitive costs, and acts as an efficient alternative to develop the drugs in a significantly less amount of time. The high-content single-cell screening process helps companies test existing psychiatric treatments on patient blood cells and predict the effectiveness of the new schizophrenia drug, depending upon the health condition of each individual.

This first-of-its-kind process will help healthcare companies overcome the limitations of first-line treatments, as these treatments have been performing poorly in most patients.

Request for COVID19 IMPACT ANALYSIS On Schizophrenia Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=67820

Study of Live Blood Cells Gives Rise to Potential Schizophrenia Drugs

One of the major challenges that restricts healthcare companies from developing novel drugs for the schizophrenia drugs market is the lack of sample-based tests. Since doctors cannot take brain tissue samples from patients like they do in a biopsy on a cancer tumor elsewhere in the body, it is challenging for researchers to study the root causes of schizophrenia. This becomes a hurdle for doctors and researchers as to what to target in order to design novel neuropsychiatric drugs. As such, healthcare companies are collaborating with doctors and researchers to study the live blood cells of patients with mental health disorders. These blood cells help researchers identify potential targets for drug discovery.

Companies are increasing focus on the study of human blood cells, as these cells are closely associated with the central nervous system. This makes blood cells an ideal environment to test potential new drugs.

Buy Now Schizophrenia Drugs Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=67820&ltype=S

Analysts’ Viewpoint

The schizophrenia drugs market is expected to grow the fastest in Asia Pacific on an account of the demand for less-invasive oral drugs that are anticipated to reach ~US$ 10.8 billion by 2027. Healthcare companies are increasing research on primary cells from patients to gain high success rates in the discovery of effective drugs. They are also innovating on antipsychotic drugs, as these drugs provide a range of tools to explore brain function in health and mental disorders. However, antipsychotic drugs have a high risk of disrupting the extrapyramidal function in patients. Also, these drugs do not have enough clinical evidence to prove their effectiveness in the development of new compounds in drugs.

As such, healthcare companies are increasing research & development to closely understand the effects of antipsychotic drugs on the central dopamine homeostasis of patients. Companies operating in the schizophrenia drugs market should focus on new models of preventive treatments of schizophrenia, such as the animal model and stem cell technology, for improved schizophrenia drug screenings.

Schizophrenia Drugs Market: Overview

· Rise in the prevalence of schizophrenia, approvals for additional indications, and launch of new schizophrenia drugs are driving the schizophrenia drugs market.

· The number of patients that are suffering from schizophrenia has been increasing across the world. Moreover, rise in the launch of new schizophrenia drugs in various countries is fueling the growth of the global schizophrenia market.

· These factors are estimated to boost the global schizophrenia drugs market during the forecast period. The schizophrenia drugs market was valued at ~US$ 11.2 Bn in 2018, and is projected to reach ~US$ 15.5 Bn by 2027, expanding at a CAGR of ~4% from 2019 to 2027.

Schizophrenia Drugs Market: Key Trends

· The market for schizophrenia drugs is an established market, owing to the high demand for schizophrenia drugs in developed as well as developing countries. Additionally, leading market players in the schizophrenia drugs market are engaged in the development of innovative products.

· Based on drug class, the global schizophrenia drugs market has been categorized into first generation drugs, second generation drugs, and third generation drugs. The second generation drugs segment held a major share of the global schizophrenia drugs market in 2018, owing to their low risk of neurological side effects as compared to first generation of schizophrenia drugs.

· In terms of route of administration, the global schizophrenia drugs market has been segregated into oral and injectable. The oral segment dominated the global schizophrenia drugs market, owing to easy accessibility to oral drugs, their non-invasive nature, and high preference by patients.

· The number of people affected by depression has been rising all across the world. According to the WHO, more than 300 million people suffer from depression and over 800,000 people commit suicide every year. Depression is the second leading cause of death in 15–29 year olds.

· Increase in the number of launches of new schizophrenia drugs in various countries is fueling the global schizophrenia drugs market.

o In 2015, Otsuka Holdings Co., Ltd. announced the launch of Rexulti in the U.S. In April 2017, the drug was also launched in Canada.

Schizophrenia Drugs Market: Competition

· The report provides the company profiles that includes key information about the major players in the schizophrenia drugs market.

· Each of these players have been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segment, and recent developments.

· The schizophrenia drugs market is highly consolidated, owing to a small number of market players selling approved drugs for schizophrenia.

· Janssen Global Services, LLC (Johnson & Johnson), ALLERGAN, Pfizer Inc., and Otsuka Holdings Co., Ltd. are major players operating in the global schizophrenia drugs market.

FDA Approval and Product Expansion

· In January 2018, Otsuka Pharmaceutical Co., Ltd. announced that it received regulatory approval for the manufacture and sales of Rexulti tablets (generic name - brexpiprazole) in Japan. Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and as an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.

· In January 2018, Janssen Global Services, LLC received FDA approval for INVEGA SUSTENNA (paliperidone palmitate), a once-monthly schizophrenia treatment drug. This is the first and only antipsychotic drug to have U.S. Food and Drug Administration (FDA) approval.

· In November 2017, ALLERGAN received FDA approval for use of VRAYLAR (cariprazine) for the treatment of schizophrenia. VRAYLAR is an oral, once-daily atypical antipsychotic drug approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar disorder, with a recommended dose range of 3 to 6 mg/day, and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5 to 6 mg/day.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Atherosclerosis Drugs Market Report Analysis With Industry Share

Atherosclerosis Drugs Market - Risk Associated with Cardiovascular Health to Drive Sales

Despite the prevalence of diabetes and cholesterol among a wide patient pool, the atherosclerosis drugs market will move at a sluggish CAGR of 2.5% during the forecast period, finds a recently published report by Transparency Market Research (TMR).

This market growth is attributable to the high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries. A sedentary, yet, demanding lifestyle instigates consumers to opt for quick dietary choices, which will catalyze revenue streams to the atherosclerosis drugs landscape.

To add to that, government initiatives at a global level have played a crucial role in improving the quality of healthcare services and infrastructure, which has been encouraging pharmaceutical companies to develop effective drugs for the treatment of various diseases. The effectiveness of drugs coupled with their easy availability through streamlined distribution channels has been complementing the sales of atherosclerosis drugs. Analyzing the current and the future growth scope, the TMR study opines that, the atherosclerosis drugs market will register a value tantamount to ~US$ 57.4 Bn by 2027.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73638

Popularity of Generic Drugs Poised to Overshadow Atherosclerosis Drugs Market Growth

In March 2019, the U.S. Food and Drug Administration approved a novel generic drug of Diovan to bridge the high demand and low supply gap of this critical drug, on account of multiple recalls of valsartan products manufactured by several brands. After two months, Zydus Cadila announced that it has received approval for Chlorthalidone, a generic version of Thalitone produced by Pfizer.

These and many companies have scrambled towards the development of generic drugs to offer the near-same benefits of branded drugs at a low cost. The rapid rise in the penetration of generic drugs in parallel to increasing awareness among consumers about the cost benefits of these drugs is likely to curb the growth potential of the atherosclerosis drugs market.

Also, heart strokes and cardiovascular dysfunction are the symptoms associated with atherosclerosis conditions, which could lead to sudden death. On account of the severity of these symptoms, the survival rate is low among patients, which reduces the diagnosis percentage of atherosclerosis.

Request for COVID19 IMPACT ANALYSIS On Atherosclerosis Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73638

Distribution Partnerships with Retail Pharmacies Will Remain Beneficial

According to the statistical data of the TMR study, retail pharmacies will grow as the key point-of-sales channel for atherosclerosis drugs, as they are established at even the remotest of locations, thereby making it convenient for consumers to present prescriptions and purchase drugs. In addition, retail pharmacists offer a more consultative role regarding the route of administration and possible side effects of drugs. Retail pharmacies have the presence of several brands, which makes them a suitable purchase point for patients. However, hospital pharmacists operate in a more clinic-oriented manner by having significant contact with doctors and nurses, and they manage their inventories with only specific brands.

By 2027, players in the atherosclerosis drugs market can look at sales through retail pharmacies to a value tantamount to ~US$ 24 Bn.

Analysts’ Take on Atherosclerosis Drugs Market

Analyzing the impact of the drivers and restraints influencing the future of the atherosclerosis drugs market, analysts of the TMR study anticipate slow, yet, steady growth during the forecast period. While favorable government policies and impressive strides of the healthcare industry are projected to foster the leaps of the North American atherosclerosis drugs market, Asia Pacific will grow at an accelerated pace during the forecast period.

An investment made towards the development of novel drugs with a keen eye on their effectiveness will help in developing a weighted product portfolio. In addition, the convergence of e-Commerce and the healthcare sector will create high sales opportunities through online pharmacies for players operating in the atherosclerosis drugs market during the forecast period.

Buy Now Atherosclerosis Drugs Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=73638&ltype=S

Atherosclerosis Drugs Market: Overview

· According to Transparency Market Research’s latest market report on the atherosclerosis drugs market for the historical period of 2017-2018 and forecast period of 2019-2027, the rising prevalence of atherosclerosis and cardiovascular disease, and development of new treatments are anticipated to drive the global atherosclerosis drugs market during the period of forecast.

· The global atherosclerosis drugs market was valued at ~US$ 45.7 Bn in 2018, and is expected to expand at a CAGR of 2.5% from 2019 to 2027.

· As such, the global atherosclerosis drugs market is projected to be valued at ~US$ 57.4 Bn by the year 2027.

Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases and Awareness About Cardiovascular Diseases: Key Drivers

· Atherosclerosis is a leading cause of vascular diseases. For instance, according to the American Heart Association, Inc., the mortality rate of vascular disease is 700 per 100,000 people per year in the country.

· Rise in the number of people with cardiovascular diseases is likely to fuel the growth of the global atherosclerosis drugs market. Obesity, unhealthy diets, and changes in lifestyles are factors leading to cardiovascular diseases. For instance, according to the American Heart Association, approximately 2,300 people died in 2018 and 92.1 million Americans are living with cardiovascular diseases.

· According to an article published in NCBI, atherosclerosis accounted for more than 90% of cases of peripheral artery disease.

· Rise in the level of low-density lipoproteins cholesterol (LDL-C) is directly associated with atherosclerosis.

· According to the Centers for Diseases Control and Prevention, between 2005 and 2012, an estimated 29 million U.S. adults had elevated total cholesterol levels. Thus, the rising level of LDL-C is likely to boost the growth of the atherosclerosis drugs market.

· Increase in incidences of cardiac arrests, heart failures, and other cardiovascular diseases have driven people to become more aware of heart failure warning signals and the importance of prompt response.

· Government participation has also played an important role in raising concerns and creating awareness about cardiovascular disease treatment.

· In 2015-2016, the American Heart Association committed to funding 980 new research projects worth over US$ 163 Mn. The organization uses donations to fund research projects. The American Heart Association funds more research on cardiovascular diseases and stroke than any organization, except for the Federal Government.

· Increase in awareness about cardiovascular diseases and atherosclerosis in developing regions is anticipated to drive the atherosclerosis drugs market. For instance, the incidence of cardiometabolic diseases, such as metabolic syndrome, abnormal obesity, hypertension, ischemic heart diseases, stroke, and diabetes, is high in South Asian countries; hence, in 1993, a professional society was started at the University of Minnesota. This society organizes a conference on the topic of atherosclerosis and thrombosis every year in India.

Atherosclerosis Drugs Market: Development of New Treatments

· Key players in the global atherosclerosis drugs market are engaged in research and development to introduce new atherosclerosis drugs.

· Rise in the prevalence and incidence of cardiovascular conditions due to plaque formation is leading to an increase in the demand for new treatment options.

· E-selectin-targeting polymer is a new polymer developed by Ben-Gurion University (BGU) and the Sheba Medical Center. It is a new therapy for atherosclerosis that reduces the risk of ischemia, stroke, arterial thrombosis, and myocardial infraction, by reducing and preventing plaque formation.

· Protein Convertase Subtilisin/Kexin type 9 (PCSK 9) is an intensive statin therapy to decrease the low density lipoprotein cholesterol level, which reduces the risk of coronary atherosclerotic plaque formation.

· New treatments for atherosclerosis are likely to fuel the growth of the global atherosclerosis drugs market.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Asthma Treatment Market Report Analysis With Industry Share Insights Shared in Detailed Report

Asthma Treatment Market: Increasing Penetration of Generic Drugs to Drive Sluggish Growth

The global asthma treatment market will rise from a value of ~US$ 25.6 Bn in 2019 to ~US$ 30.5 Bn by 2027, and it is anticipated that an increase in the number of FDA-approved products in parallel to the increasing awareness among asthma patients regarding quality care will drive the steady odyssey of the market.

Analysts at Transparency Market Research (TMR) anticipate that, among the strategic approaches taken towards consolidation, partnerships and collaborations will remain integral to maximize profitability from new markets. Having witnessed product recalls, manufacturers in the asthma treatment market are dedicating ample efforts to develop high-quality products, which are likely to receive easy approvals from the FDA and similar regulatory bodies.

On the demand side, as awareness regarding quality care for the treatment of asthma increases among patients, the adoption of inhalers and oral drugs is likely to increase. However, in recent times, the cost-benefits of generic drugs have been appealing to patients, which could pose as a challenge for manufacturers in the asthma treatment market.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73640

Consumer Shift towards Alternative Therapies to Impede Revenue of Asthma Treatment Market

The consumption of antibiotics for the treatment of asthma has always been debatable, given their side-effects such as include sore mouth and throat, dysphonia, cough, and spasms of the trachea. In addition, several patients have also complained of suffering from headaches, increased heart rates, and tremors, post the intake of drugs, which has instigated the quest for asthma treatment that is free from any side-effects, such as alternative therapies.

Despite not being branded as the mainstream treatment, individuals in the modern era are showing a marked proclivity for alternative therapies as an additional measure to treat asthma. Another challenge for market players is the mounting amount of literature that claims the effectiveness of alternative therapies when practiced for a prolonged period of time. This has attracted the interest of practitioners as well as asthma patients towards alternate therapies, as such impeding the growth of the global asthma treatment market.

The trend of practicing Yoga and Unani is gaining traction, and is more pronounced in Asia Pacific, which also happens to be the home to these therapies. Also, a high number of medical tourism activities observed in the region are likely to pass on the trend to developed countries, which could negatively impact the sales of drugs and devices related to asthma, thereby stunting the growth of the asthma treatment market space.

Long-term Asthma Control Medications to Outperform Quick-relief Medications

According to statistical data reported by the TMR study, the sales of long-term asthma control medications accounted for a value equal to ~US$ 14 Bn in 2018, and these drugs are projected to fast-penetrate the end-user space at a rate of ~3% during 2019-2027. A spurt in the growing popularity of these medications is due to the increase in the adoption of combination drugs for treating asthma, coupled with several studies establishing their effectiveness, when consumed for a prolonged duration.

Quick-relief medications have use only during asthma attacks, which makes them a less-significant drug in the asthma treatment market. To add to that, a high number of patent expirations and the advent of generic variants are further projected to impede their sales potential during the forecast period.

Request for COVID19 IMPACT ANALYSIS On Asthma Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73640

Asthma Treatment Market: Analysts’ View

Authors of the report opine that, the asthma treatment market will grow at a slow, yet steady pace, as long-term asthma control medications will bring continuous sales opportunities. Hospital pharmacies with the ability to maintain large inventories with essential drugs are likely to remain crucial; however, an increasing number of retail pharmacies, coupled with their easy accessibility, will drive significant revenue to the asthma treatment market. As the healthcare industry braces itself to embrace digitalization, online pharmacies will overcome the limitations of physical exposure in overseas territories.

Asthma Treatment Market: Key Insights

· Long-term asthma control medications and quick-relief (rescue) medications are the two types of drugs used to treat asthma.

· Rescue inhalers and controller inhalers are used to treat the symptoms of asthma. However, to manage severe asthma cases, longer-acting inhalers are required, which can keep the airways open (formoterol, salmeterol, tiotropium) as well as be used as inhalant steroids.

· Major types of long-term asthma control medications include combination inhalers, inhaled corticosteroids, long-acting beta agonists, leukotriene modifiers, theophylline, and others (reslizumab, benralizumab, etc.).

· The combination inhalers sub-segment dominated the long-term asthma control medications segment in the asthma treatment market in 2018. The growth of this sub-segment can be attributed to the increase in the demand for combination inhalers, and promising drugs in the pipeline of the market.

· The global asthma treatment market covers all drug types for different routes of administration to treat asthma in patients. Several drug companies are focusing on the development of promising drug molecules to improve treatment measures, which are beneficial for patients, by collaborating with research institutes and others companies. These factors are projected to drive the market during the forecast period.

Buy Now Asthma Treatment Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=73640&ltype=S

Asthma Treatment Market: Drivers

· Asthma prevalence has been increasing despite advancements in treatment in the past two decades. Due to this, the global asthma treatment market is also expanding. Asthma prevalence ranges from 3% to 5% in developing countries, to less than 20% in developed countries, affecting people of all ages.

· Focus on spreading awareness about asthma treatment, including common treatment options such as pressurized meter dose inhalers and dry powder inhalers, is fueling the global market.

· Increase in the success rate of asthma treatment using combination therapy, such as long-acting muscarinic antagonist-inhaled corticosteroid (LAMA-ICS), long-acting β2-agonist-inhaled corticosteroid (LABA-ICS), and other combination drugs, and recent regulatory approvals have propelled the adoption of combination therapy in the global asthma treatment market.

· Rising focus on smart or digital inhalers for the administration of asthma drugs is driving the global market.

· The asthma treatment market is anticipated to be driven by increase in product approvals by the FDA and other regulatory bodies, rise in the prevalence of asthma, and strategic approaches such as collaborations & partnerships by market players. Rise in the opportunities for market players to expand their geographical presence in emerging countries will fuel the growth of the global asthma treatment market.

Asthma Treatment Market: Key Segments

· The global asthma treatment market has been segmented based on treatment type, route of administration, and distribution channel.

· Under treatment type, the global market is dominated by the long-term asthma control medications segment, which will continue over the forecast period.

· Under distribution channel, the global market is dominated by the retail pharmacies segment, which is expected to continue through the forecast period.

Asthma Treatment Market: Key Regions

· In terms of region, the global asthma treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.

· North America holds a major share of the global market, while Asia Pacific is projected to expand at the highest CAGR over the forecast period.

Asthma Treatment Market: Major Players

· The global asthma treatment report concludes with the company profiles section that includes key information about the major players in the market.

· Leading players analyzed in the report are

o Mylan N.V.

o AstraZeneca plc.

o Boehringer Ingelheim International GmbH

o F. Hoffmann-La Roche Ltd

o GlaxoSmithKline plc.

o Merck & Co., Inc.

o Novartis AG

o Sanofi

o Sunovion Pharmaceuticals, Inc.

o Teva Pharmaceutical Industries

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Burn Injury Treatment Market Report Analysis With Industry Share

Burn Injury Treatment Market: Topical Treatments Prevent Risks of HAI

Severe burn injuries can lead to increased morbidity and mortality rates in the healthcare space. This is why, healthcare providers in the burn injury treatment market are developing efficacious treatment options for patients.

One of the major challenges that patients with burn injuries face is the risk of hospital-acquired infections (HAI). This is well explained, as highest revenue in the burn injury treatment market came from hospitals, which accounted for ~US$ 1.3 billion in 2018. Wherefore, healthcare providers in hospitals and clinics are increasing the availability of topical treatments to prevent the risk of hospital-acquired infections.

To reduce the incidences of hospital acquired infection in patients, healthcare companies of the burn injury treatment market are introducing improved silver sulfadiazine (SSD) creams that reduce complications and other health risks. Healthcare professionals are seeking the expertise of researchers and scientists to experiment on silver-containing dressings with honey, as honey provides antiseptic effects for the faster healing of burn injuries. Companies are increasing research on dressings infused with sodium hypochlorite that show faster healing results as compared to SSD dressings.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73694

Hydrogel Dressings Reduce Trauma in Pediatric Burn Patients

Burn injuries lead to painful and traumatic experiences, especially in children. Hence, there is the growing need for enhanced treatment alternatives in the burn injury treatment market that reduce pain and anxiety in pediatric burn patients.

The revenue of traditional dressing products is projected to reach ~US$ 1.4 billion by 2027, in the burn injury treatment market. Thus, healthcare companies are developing result-oriented hydrogel dressings to capitalize on the market trend. Hydrogel dressings help reduce re-epithelialization time as compared to conventional plastic wrap used for the treatment of pediatric burn patients. As a result, parents and healthcare professionals are turning towards hydrogel dressings to provide pain relief via the evaporative cooling agents present in the dressing, which soothes exposed nerve endings in the skin.

Depending on the degree of burn, manufacturers in the burn injury treatment market are innovating on skin care products such as aloe vera cream and antibiotic ointments. As many patients are more comfortable taking medications, healthcare companies are introducing pain medications such as acetaminophen (Tylenol) for first-degree burns.

Request for COVID19 IMPACT ANALYSIS Burn Injury Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73694

Improved Skin Regeneration Therapies Overcome Treatment Obstacles

Tissue regeneration technology has achieved important milestones in the burn injury treatment market. However, its limitations are a great concern for healthcare providers. For instance, commercial products such as Epicel and Cryoskin are mostly non-permanent bioactive materials in dressings. In many cases, immune rejection has been reported by patients who opted for skin-regeneration dressings with allogeneic fibroblasts and keratinocyte materials. Hence, healthcare providers are increasing the capabilities of skin-regeneration therapies using cytokines and ECM (Extracellular Matrix).

Collagen-based products have the highest revenue among biological products, with an estimate of ~US$ 276 million by 2027, in the burn injury treatment market. This is not surprising, as healthcare providers are developing product designs that provide similar skin composition to collagen types I and III, which are native tissues in the human body. However, collagen possesses poor mechanical properties. Hence, scientists and healthcare companies are improving collagen-based products by cross-linking collagen with synthetic materials for developing better skin-regeneration treatment options.

Buy Now Burn Injury Treatment Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=73694&ltype=S

Analysts’ Viewpoint on Burn Injury Treatment Market

Manufacturers in the burn injury treatment space are developing less-invasive treatment options such as antibiotic creams and ointments that heal second-degree burns. They are also increasing research on the techniques of skin grafting with the use of synthetic skin for the treatment of third-degree burns. Severe burns that have affected large parts of the body need profound treatment options such as intravenous (IV) antibiotics to prevent infection. However, stakeholders in the healthcare space are questioned about the social challenges that patients may come across after getting discharged from the hospital. Thus, healthcare providers should develop efficacious skin regeneration therapies using plant cells that mimic the native tissue cells of the human body.

Burn Injury Treatment Market: Overview

· According to Transparency Market Research’s latest market report on the burn injury treatment market for the historical period of 2017–2018 and forecast period of 2019-2027, increase in the prevalence of burn injuries, rise in the adoption of artificial skin substitutes, and surge in the demand for advanced treatment are factors anticipated to drive the global burn injury treatment market.

· According to the report, the global burn injury treatment market was valued at ~US$ 2.6 Bn in 2018, and is expected to expand at a CAGR of ~5% from 2019 to 2027.

· As such, the global burn injury treatment market is projected to be valued at ~US$ 4 Bn by the year 2027.

Increase in Prevalence of Burn Injuries and Rise in Awareness to Drive Market

· There has been an increase in the prevalence rate of burn injuries, which is leading to a rise in the demand for burn injury treatment products.

· Growing awareness of personal hygiene and personal care among the population, leading to a surge in the adoption rate of wound care products, is anticipated to drive the growth of the burn injury treatment market. The affordability of high-end burn injury treatment products has also increased in developing countries, which is expected to boost the purchasing power of patients.

· According to WHO, 265,000 deaths occur every year due to burns; a majority of these are preventable with proper treatment. Approximately 96% of burns occur in low- and middle-income countries, highlighting significant treatment penetration in developed countries.

· According to the American Burn Association, in the U.S., an estimated 486,000 burn injuries were recorded at emergency departments between 2011 and 2015.

Burn Injury Treatment Market: New Product Development and Technological Advancements

· Key players in the burn injury treatment market are engaged in the development of technologically-advanced products for burn injury treatment. For instance, Acelity L. P., Inc. is expanding and deepening its global footprints in the advanced wound care segment through innovations in NPWT and incision management systems. The company is also focused on innovating within services and customer support offerings. It has also launched the iOn Healing mobile application.

· Technological advancements in burn injury treatment, such as endovascular arterial repair techniques and bi-layered human dermal substitutes, are projected to drive the burn injury treatment market.

· In September 2016, ConvaTec, Inc. announced a new addition to its existing line of surgical dressings with the launch of the AQUACELL AG Surgical dressing. AQUACELL AG is an antimicrobial dressing used to prevent wound infection.

· The adoption of such technologically-advanced solutions for the treatment of burn injuries is likely to fuel the growth of the global market in the near future.

High Cost of Advanced Wound Care Products and Unfavorable Reimbursement Policies to Hamper Market

· Cost is a major factor influencing the selection of a treatment option. Due to high costs, conventional wound healing products are preferred over technologically-advanced dressings, despite their slow healing process.

· Price-sensitive markets, mainly underdeveloped countries, are anticipated to witness slow adoption of advanced burn injury treatment technologies.

· Specialized complex care in burn injury treatment is often challenged by unfavorable reimbursement policies. Ever-changing and new reimbursement guidelines are tedious to follow and understand.

· In some cases, wound care surgery is performed in outpatient settings, which do not require an overnight stay. Hence, such therapy is not considered for coverage by the reimbursement system of healthcare settings. This factor is anticipated to restrain the expansion of the global burn injury treatment market.

Global Burn Injury Treatment Market: Competition Landscape

· This report profiles the major players in the global burn injury treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

· Prominent players operating in the global market include

o Integra LifeSciences Corporation

o Cardinal Health

o Mölnlycke Health Care AB

o Essity Aktiebolag

o Smith & Nephew plc

o Acelity L.P., Inc.

o B. Braun Melsungen AG

o 3M Healthcare

o ConvaTec, Inc.

o Coloplast Group.

Burn Injury Treatment Market: Key Developments

Key players in the global burn injury treatment market are engaged in the development of new products, key mergers & acquisitions, and collaborations. Major developments by industry players are likely to fuel the expansion of the global burn injury treatment market. Some of the growth strategies adopted by players in the market are as follows:

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report Analysis With Industry Share Insights Shared in Detailed Report

Innovations in Combination Therapy to Dominate COPD Treatment Market

The chronic obstructive pulmonary disease treatment market is projected to be valued at ~US$ 26.2 billion in the year 2027. The high prevalence of chronic obstructive pulmonary disease (COPD) and the need for improved treatment options are catalyzing market growth.

To meet the needs of patients, healthcare companies in the COPD treatment market are developing efficacious treatment options in combination therapy. Revenue of combination therapy was valued at ~US$ 9.6 billion in 2018; the highest amongst all the drug classes in the chronic obstructive pulmonary disease treatment market.

With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73763

Dual and Triple Therapies Minimize Moderate and Severe Exacerbations

With ongoing developments in the chronic obstructive pulmonary disease treatment market, healthcare companies are weighing the responses and combination of therapies in patients. As such, there is a strife between the credibility of dual combination therapy and long acting bronchodilators for treatment in COPD patients.

To achieve greater effectiveness of therapies in the chronic obstructive pulmonary disease treatment market, manufacturers have integrated combinations of bronchodilators to treat patients with moderate to severe COPD. This includes the combination of long acting beta agonist (LABA) with long acting muscarinic antagonist (LAMA). Thus, the LAMA and LABA group of inhalers are considered safe and effective in COPD patients.

Also, triple therapy has shown better outcome in patients as compared to single-agent LAMA monotherapy in the COPD treatment market. Compared with LAMA monotherapy, triple therapy helps to drastically reduce moderate or severe exacerbations. Thus, healthcare companies are making significant improvements to enhance triple therapy against dual therapy LABA/LAMA.

Request for COVID19 IMPACT ANALYSIS ON Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73763

Improved Bronchodilators Reduce Reversibility in Patients

Stakeholders in the chronic obstructive pulmonary disease treatment landscape are developing methods to reduce emphysema and the mortality rates of patients. This has instigated the need for combined bronchodilator response (BDR) in patients. Revenue of bronchodilators in the COPD treatment market is estimated to reach a value of ~US$ 5.5 billion by 2027; the second-highest amongst all drug classes. This is why, healthcare professionals are taking regular follow-ups on patients with combined-BDR. However, the results in combined-BDR are associated with greater frequency of exacerbations and symptoms of asthma. Thus, healthcare companies are increasing research to identify patients with asthma-COPD overlaps, and developing treatment alternatives that result in improved outcomes.

Studies published in the European Respiratory Journal stated that, bronchodilator reversibility might not distinguish asthma from COPD. It was also found that, the prevalence of bronchodilator reversibility was higher in patients with COPD than in asthma patients. Thus, with the help of bronchodilator response testing, healthcare companies are developing improved prebronchodilators that minimize the adverse effects in patients.

Analysts’ Viewpoint on COPD Treatment Market

The chronic obstructive pulmonary disease treatment market is anticipated for high growth during the forecast period. Although retail pharmacies dominate more than half of the market share, online pharmacies are expected to experience steady growth in the market. Healthcare companies are introducing digital inhalers with built-in sensors for patients suffering from COPD. For instance, in December 2018, Teva Pharmaceutical Industries — a leading Israeli multinational pharmaceutical company, announced the launch of ProAir® Digihaler™ — a digital inhaler with Bluetooth wireless technology for patients with asthma and COPD. However, healthcare companies are developing improved therapies to reduce the reversibility of inhalers in patients. Thus, manufacturers should focus on increasing triple therapy treatment options to effectively minimize exacerbations.

Buy Now Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=73763&ltype=S

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Overview

· According to Transparency Market Research’s latest report on the chronic obstructive pulmonary disease (COPD) treatment market for the historical period of 2017-2018 and forecast period of 2019-2027, increasing burden of chronic obstructive pulmonary disease, rise in geriatric population, and surge in product approvals and launches are expected to boost the global chronic obstructive pulmonary disease treatment market during the forecast period.

· According to the report, the global chronic obstructive pulmonary disease treatment market was valued at ~US$ 17.4 Bn in 2018. The COPD treatment market is expected to expand at a CAGR of ~5% from 2019 to 2027.

Increase in Prevalence of Chronic Obstructive Pulmonary Disease: A Key Driver of COPD Treatment Market

· Chronic Obstructive Pulmonary Disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management, and this is anticipated to drive the global chronic obstructive pulmonary disease treatment market.

· Tobacco smoking could also lead to COPD, as such, boosting the COPD treatment market. The number of adults addicted to smoking has been increasing. Other risk factors include occupation and indoor air pollution. According to the WHO, the primary cause of COPD is exposure to tobacco smoke (either active smoking or passive smoking).

· According to an article published by Medscape in April 2019, the prevalence of COPD, worldwide, varies between 7 - 19%. The Burden of Obstructive Lung Disease (BOLD) study found a global prevalence of 10.1%. Men have a pooled prevalence of 11.8%, while it has a prevalence of 8.5% in women. The numbers vary across different regions around the world. Cape Town, South Africa, has the highest prevalence, affecting 22.2% of men and 16.7% of women.

· According to a report by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2018, the prevalence and burden of COPD are projected to increase in the near future, due to continued exposure to COPD risk factors and aging of the world’s population, which is thereby boosting the growth of the chronic obstructive pulmonary disease treatment market.

Increase in Adoption of Combination Therapy: A Key Driver of COPD Treatment Market

· Combination therapy includes LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs, which are anticipated to drive the chronic obstructive pulmonary disease treatment market.

· The adoption of combination therapy is increasing, as it is more effective than separate use of bronchodilator and corticosteroid. There has been an increase in the number of patients being successfully treated with combination therapy, who were not showing signs of recovery with bronchodilators or corticosteroids treatments, which is thereby boosting the growth of the COPD treatment market.

· Combination therapy is more effective than monotherapy for improving the symptoms and quality of life.

· Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labour and Welfare (MHLW), which is a cabinet level ministry of the Japanese government, have approved the use of combination drugs for the treatment of COPD. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. received authorization from the European Commission for the expanded use of once-daily Trelegy Ellipta, the first single inhaler triple therapy indicated for COPD patients who were not adequately treated with dual bronchodilation. These drugs have a longer patent cover, i.e., till 2030, which will lead to high valuation of the chronic obstructive pulmonary disease treatment market.

· In April 2019, the FDA approved the combination therapy for COPD maintenance. A fixed-dose combination of long-acting muscarinic antagonist (LAMA) aclidinium bromide (400 mcg) and long-acting beta-agonist (LABA) formoterol fumarate (12 mcg) has been approved by the FDA for the maintenance and treatment of chronic obstructive pulmonary disease.

· Increase in the success rate of combination therapy for COPD treatment and recent regulatory approvals have propelled the adoption of combination therapy in COPD management, thereby boosting the growth of the COPD treatment market.

Patent Expiry of Branded Products and Availability of Generic Equivalents Hamper Market

· Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by a patent holder. The patent expiry of branded drugs has a significant impact on the pharmaceutical industry.

· In case of the COPD treatment market, a few of the players face the threat of patient expiry, which further increases the availability of generic versions of drugs and creates pricing pressure on manufacturers.

· Patent expiry declines revenue generated from the sales of branded drugs, and can affect the market share of a company. For instance, Flixotide/Flovent, Advair, and Serevent are major respiratory products manufactured by GlaxoSmithKline, which are now facing patent expiry. This is likely to lead to a decline in sales, thereby affecting the company’s market position. In January 2019, the FDA approved Mylan's Wixela Inhub, the first generic version of Advair Diskus for the treatment of asthma and COPD.

· The availability of generic versions of medicines in the market affects the sales of branded drugs in developed regions such as North America and Europe, and causes pricing pressure, as such, restraining the growth of the chronic obstructive disease treatment market.

Global Chronic Obstructive Pulmonary Disease Market: Competition Landscape

· This report profiles major players in the global COPD treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

Prominent players operating in the global chronic obstructive pulmonary disease treatment market include

· AstraZeneca

· Boehringer Ingelheim International GmbH

· GlaxoSmithKline plc

· Novartis AG

· Teva Pharmaceutical Industries Ltd.

· Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)

· CHIESI Farmaceutici S.p.A.

· Orion Corporation

· Mylan N.V.

Global Chronic Obstructive Pulmonary Disease Treatment Market: Key Developments

Key players in the global chronic obstructive pulmonary disease treatment market are engaged in the development of new products, key mergers & acquisitions, collaborations, and integration. Major developments by industry players are likely to fuel the expansion of the global COPD treatment market. Some of the growth strategies adopted by players in the global chronic obstructive pulmonary disease treatment market are as follows:

· In January 2019, CHIESI Farmaceutici S.p.A. entered into an exclusive global license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. This agreement is aimed at developing innovative molecules for use in the treatment of respiratory diseases.

· In November 2018, GlaxoSmithKline plc and Innoviva, Inc. announced authorization from the European Commission for the expanded use of once-daily Trelegy Ellipta, the first single inhaler triple therapy indicated for COPD. This expansion would help the company to cater to the treatment needs of COPD patients who were not receiving adequate treated with dual bronchodilation.

· In March 2015, AstraZeneca acquired Actavis’ branded respiratory business in the U.S. and Canada, with the aim to strengthen its product portfolio in the respiratory business. AstraZeneca owned the rights for branded respiratory drugs such as TudorzaTM PressairTM, Duaklir Genuair, and Daliresp (roflumilast).

The report on the global chronic obstructive pulmonary disease treatment market discusses individual strategies, followed by the company profiles of manufacturers of COPD treatment options. The ‘Competition Landscape’ section is included in the COPD market report to provide readers with a dashboard view and a company market share analysis of key players operating in the global chronic obstructive pulmonary disease treatment market.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Sepsis Therapeutics Market Report Analysis With Industry Share Insights Shared in Detailed Report

Third-generation Drugs and Antimicrobial Therapy to Combat Septic Infections

The severity of the septic process and the extent of organ dysfunction in patients require immediate admission to an ICU in hospital. To avoid extreme fatalities and admission to ICUs, healthcare companies in the sepsis therapeutics market are developing efficacious fourth- and fifth-generation drugs.

Revenue of cephalosporin drugs is projected to be the highest in 2027, in the sepsis therapeutics market, with an estimated value of ~US$ 2.2 billion. Thus, to gain positive outcome via clinical trials, manufacturers are collaborating with researchers & scientists to develop effective cephalosporin drugs. As such, healthcare institutions are approaching the combination therapy with third-generation cephalosporin and a tetracycline analogue to treat vibrio vulnificus infection in patients. This therapy has been gaining prominence in the sepsis therapeutics market, since the combination works as an 'in vitro' bactericidal activity against vibrio vulnificus.

Healthcare professionals are increasingly adopting antimicrobial therapy to minimize the damage caused by infections to the gut microbiome. As such, healthcare providers in the sepsis therapeutics market are delivering the right balance between the utilization of antimicrobials and the clinical need for treating specific signs and symptoms in patients.

Immunometabolism Delivers Insights on New Therapeutic Targets

Healthcare companies in the sepsis therapeutics market are increasing research on immunometabolism, as insights on immune regulation are helping manufacturers develop efficacious drugs. Since the early detection and treatment of sepsis is critical, researchers are studying the body’s natural and innate response to various classes of drugs by studying immunometabolism. To gain further insights, healthcare companies are running clinical trials involving antibiotics, fluids, and dialysis, to ensure blood flow to the affected organs. They are also devising methods of surgical therapies to remove damaged tissues.

As such, healthcare companies in the sepsis therapeutics market are trying to identify new therapeutic targets that could potentially reduce inflammatory response in patients. They are increasing research via animal testing by introducing lipopolysaccharide (LPS) in mice to see if the molecule can suppress the severity of inflammatory response.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19565

Judicious Prescriptions and New Antimicrobial Agents Reduce Drug Resistance

Antimicrobials have a rapid and long-lasting effect on septic infections. However, antimicrobial resistance to gram-positive infections (GPIs) is emerging as a major public health threat to patients, worldwide. The growing prevalence of multidrug-resistant bacteria in patients has led to increased morbidity and mortality rates. This has created the issue of escalated treatment costs and prolonged hospitalization stay for patients. This is why, healthcare companies in the sepsis therapeutics market are developing new antimicrobial agents to reduce the resistance of drugs against gram-positive infections.

Healthcare companies are expected to develop a robust healthcare value and supply chain in the Asia Pacific region, as it is predicted for fast growth in the sepsis therapeutics market. For instance, stakeholders in the sepsis therapeutics market have observed the growing prevalence of methicillin resistant staphylococcus aureus bacteria in Indian patients that has led to the heavy consumption of antibiotics. Thus, stakeholders in the sepsis therapeutics market are recommending judicious prescription of antimicrobial agents, implementation of antibiotic stewardship programs, and conformation to suitable antibiotic policies developed by health commissions to reduce the problem of drug resistance in patients.

Request for COVID19 IMPACT ANALYSIS ON Sepsis Therapeutics Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=19565

Analysts’ View of Sepsis Therapeutics Market

The sepsis therapeutics market is predicted to exponentially grow from a value of ~US$ 3.2 billion that was accounted in 2018, to a value of ~US$ 6 billion by 2027. Healthcare providers are practicing early therapeutic plasma exchange in cases of septic shock in patients. This method is considered medically safe, and effective for septic shock patients. They are also introducing high doses of vasopressors for rapid hemodynamic improvement and favorable changes in the cytokine profile for patients observed with septic shock. However, in the case of GPIs, adverse effects related to safety and tolerability towards drugs is an ongoing challenge for healthcare companies. To overcome this challenge, manufacturers should introduce new antimicrobial agents in efficacious fourth- and fifth-generation drugs.

Sepsis Therapeutics Market: Overview

According to the latest report published by Transparency Market Research on the global sepsis therapeutics market for the historical year of 2017 and forecast period of 2019 to 2027, rise in investments in research & development and novel pipeline drugs are projected to boost the growth of the global sepsis therapeutics market during the forecast period.

The global sepsis therapeutics market generated ~US$ 3.2 Bnrevenue in 2018, and is expected to expand at a CAGR of 5% from 2019 to 2027.

Buy Now Sepsis Therapeutics Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=19565&ltype=S

Novel Pipeline Drugs and Rise in Incidence Rate of Sepsis: A Key Driver

The geriatric population is prone to developing sepsis, and is expected to increase the patient pool across the world, which, in turn, is projected to drive the sepsis therapeutics market during the forecast period.

According to the United Nations University (UNU), the percentage of the world population above 65years of age is anticipated to increase from 9% in 2010 to 16% by 2050.

Rise in the epidemiological burden of sepsis increases the demand for the development of drugs for the treatment of sepsis. This is likely to boost the growth of the sepsis therapeutics market.

Leading pharmaceutical companies are striving to address these unmet medical needs through new product development.

Asahi Kasei Corporation is planning to launch ART-123by 2021 for the treatment of sepsis. The drug has shown positive results for phase III clinical trial for sepsis, which would support the advancement of drugs for phase IV studies.

New approval and commercialization of novel therapeutic drugs under clinical trial studies are projected to be a major driver of the global sepsis therapeutics market from 2019 to 2027.

Cephalosporin Drug Class Prominent

The cephalosporin segment dominated the global sepsis therapeutics market in 2018, and is expected to account for a major market share during the forecast period, as third-generation cephalosporins are commonly used to treat neonatal and infant sepsis. Cephalosporins also have the broadest gram-negative bacterial coverage. This is likely to drive the cephalosporin segment during the forecast period.

The others segment is projected to grow at significant CAGR during the forecast period. The use of combination therapy for the treatment of sepsis, such as cephalosporin plus an aminoglycoside, is a driving factor that is expected to propel the segment from 2019 to 2027.

Intravenous Administration Popular

The most common way to administer antibiotics is intravenously, as intravenous antibiotics reach tissues faster and at higher concentrations than oral antibiotics. The preference of the intravenous route for administration of drugs is expected to propel the segment during the forecast period.

North America to Dominate Global Sepsis Therapeutics Market

North America accounted for a major share of the global market in 2018, followed by Europe. The high prevalence and rise in incidence of sepsis in the U.S. and Canada, wide base of pharmaceutical companies in the U.S., and easy availability of drugs in the region were key factors responsible for the prominent share held by North America in the global sepsis therapeutics market in 2018.

According to a study published in the National Center for Biotechnology Information (NCBI), around 300 people per 100,000individuals in the U.S. are affected by severe sepsis and septic shock

Europe was also an attractive market for sepsis therapeutics in 2018. High budget for research & development in the field of sepsis treatment and various initiatives taken by private and government institutions to promote awareness about sepsis are estimated to propel the market in Europe during the forecast period. Furthermore, well-established healthcare facilities, new product approvals, and commercialization and favorable medical reimbursement policies are anticipated to drive the market in the region.

The market in Asia Pacific is estimated to grow at a faster pace than other regions during the forecast period, due to increase in the focus on the development of healthcare infrastructure by public as well as private hospitals, along with a rise in the demand for novel therapeutics among a significant patient population. The sepsis therapeutics market in Asia Pacific is driven by a large pool of patients with sepsis in China and Japan, and rise in investments by leading players in the region for the establishment of distribution channels.

Global Sepsis Therapeutics Market: Competitive Landscape

Detailed profiles of the manufacturers of sepsis therapeutics have been provided in the report to evaluate their key product offerings, financials, business strategies, and recent developments.

Key players operating in the global sepsis therapeutics market include -

INOTREM S.A.

Mylan N.V.

Asahi Kasei Corporation

Pfizer, Inc.

GlaxoSmithKline plc

RegeneRx

Adrenomed AG

AtoxBio

Endacea, Inc.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Systemic Inflammatory Response Syndrome Treatment Market Report Analysis With Industry Share Insights Shared in Detailed Report

Public & Private Investments to Foster Growth of Systemic Inflammatory Response Syndrome Treatment Market

The systemic inflammatory response syndrome treatment market is anticipated to grow from ~US$ 9.8 Bn in 2019 to ~US$ 17.8 Bn by 2027, and this healthy growth is attributable to government initiatives taken towards reducing the mortality rate of patients diagnosed with sepsis. Advancements in SIRS therapeutics are further brought in due to investment firms established in developed countries, who fund numerous clinical development programs that possess the capability of formulating effective drugs.

According to the World Health Organization, 7/100 hospitalized patients are highly susceptible to infections, which can cause sepsis. The patient-susceptibility rate in developing countries exceeds even this seven-one-hundred ratio, which signifies profitable opportunities for the systemic inflammatory response syndrome treatment market, as consumers tend to gain financial lucidity along with health consciousness.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73808

Popularity of SIRS Treatment to Remain High for Treatment of Urinary Tract Infection

The TMR study finds that, revenue from the treatment of urinary tract infection will increase at a CAGR of ~8%, as dehydration, menopause, high consumption of birth control pills, and frequent involvement in sexual activities are leading causes of UTI. According to medical studies, a female’s body has a shorter urethra than a male’s body, which shortens the distance for bacteria to reach the bladder. This makes women more prone to UTI infections as compared to men, and the participation of women in availing SIRS treatment is also high. However, infections caused by unhygienic conditions that lead to the prevalence of autoimmune diseases are likely to hold significant value in the systemic inflammatory response syndrome treatment market during the forecast period.

Introduction of Effective Therapies and Drugs to Catalyze Market Growth

As concerns regarding the gravity of sepsis increase, market players operate within the range of innovation to develop effective drugs and therapeutics. Among other therapies, CytoSorb®, a specific extracorporeal cytokine adsorber, is emerging as an effective therapy to reduce inflammation and control the failure of vital organs, such as the lungs, kidneys, heart, and brain. Also, as demand for the initial-stage diagnosis of sepsis becomes more prominent, biomarkers were introduced for early detection, treatment, and disposition of the condition.

Besides therapies, ample efforts backed by central and private funding are leading to the development of numerous pipeline drugs. For instance,

Adrenomed AG introduced Adrecizmab, which is deemed effective for the treatment of septic shock. The drug also holds efficiency in preventing vascular damage and keeping intact ideal vascular functions. Led by efficiency, therapeutics and pipeline drugs are projected to uphold demand in the systemic inflammatory response syndrome treatment market.

Since developed countries remain at the forefront for the development of advanced therapies and drugs, given their sound technical knowledge, partnerships with players in developing countries are seen as a strategic move to gain a reciprocal advantage in the SIRS market. For instance, CytoSorbents Corporation collaborated with Biocon Ltd. to create a huge market for the sales of CytoSorb in overseas territories.

Analysts’ View

Authors of the report infer that, the growth of the systemic inflammatory response syndrome treatment market will be upheld by the technology-intensive approach taken by manufacturers toward the development of sepsis treatment. Extracorporeal blood purification techniques for immunomodulation are gaining momentum in the SIRS treatment market as a potential therapy, while biomarkers and antibody-modified conduits are growing in importance as effective therapeutics.

Leading on the technological scale, North America is anticipated to remain a key investor in the systemic inflammatory response syndrome treatment market. Also, well-established infrastructure, coupled with magnified focus on the sterility of operation units in the healthcare sector of the region, further complements market growth. However, increasing medical tourism and substantial improvements in the healthcare quality of developing countries in Asia Pacific will bring profitable deals for players in the SIRS market.

· According to Transparency Market Research’s latest market report on the systemic inflammatory response syndrome treatment market for the historical period of 2017 - 2018 and forecast period of 2019 - 2027, rise in the prevalence of systemic inflammatory response syndrome (SIRS) and increase in knowledge about SIRS among healthcare professionals boosts the growth of the global systemic inflammatory response syndrome treatment market.

· The global systemic inflammatory response syndrome treatment market was valued at ~US$ 9.3 Bn in the year 2018, and is expected to expand at a CAGR of ~8% from 2019 to 2027, to reach a value of ~US$ 17.8 Bn by 2027.

Request for COVID19 IMPACT ANALYSIS ON Systemic Inflammatory Response Syndrome Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73808

Rise in Prevalence of SIRS: A Key Driver

· Systemic inflammatory response syndrome SIRS is one of the major criteria for determining post-surgical complications and end-organ dysfunction. Development of the syndrome is related to long hospital stay, high incidence of multiple organ dysfunction, and increased morbidity.

· SIRS is among the common post-operative complications in cardiac surgery, leading to organ dysfunction or even death. The prevalence of SIRS among pediatric patients is expected to increase in the near future. An article published by the University of Colorado School of Medicine stated that, out of 56,210 visitors to emergency departments during a 1-year study period, 40,356 pediatric patients met inclusion criteria. Among the included study population, patients with SIRS vital signs accounted for 92.8% of all the visits with fever >38.5°C.

· An article published by the U.S. National Library of Medicine National Institutes of Health indicated that, out of 372,844,465 visits to the emergency department from 2007 to 2010, an estimated 17.8% ED visitors had SIRS, i.e., 16.6 million adult ED visits with SIRS per year. This retrospective study was conducted as a part of the National Hospital Ambulatory Medical Care Survey (NHAMCS) for four years. The study concluded that SIRS is quite common among visitors to the ED.

· An article published by the American Academy of Neurology stated that, of the 780 patients with ICH, 21.8% developed non-infectious SIRS and 37.3% developed sepsis during hospitalization.

· Therefore, steady rise in the prevalence of SIRS is likely to drive the global systemic inflammatory response syndrome treatment market during the forecast period.

Buy Now Systemic Inflammatory Response Syndrome Treatment Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=73808&ltype=S

Systemic Inflammatory Response Syndrome Treatment Market: Novel Treatment Approaches

· Cytokine Adsorption: Cytokine adsorption is one of the promising removal technologies for SIRS. Animal and human studies suggest both, pro- and anti-inflammatory cytokines interact in a complex manner and influence the immune system causing multiple end-organ effects. Cytokine adsorption therapy offers a prospective solution to improve outcomes following SIRS.

· Biomarkers: Biomarkers have the potential to improve ED-based diagnosis, treatment, and disposition of SIRS patients. Articles published in a number of journals have highlighted the role of biomarkers in SIRS, and over 100 clinical trials are currently enrolling patients for biomarker testing in sepsis. Currently, there are no biomarkers universally accepted for diagnosis and treatment.

Limited Availability of Therapeutics for SIRS Hampers Market

· Currently, no effective drug for the treatment of SIRS is available in the market. In June 2002, Ono Pharmaceutical Co. Ltd. launched Elaspol 100 for Injection, the world's first drug for acute lung injury associated with SIRS.

· However, the net sales of the drug declined from US$ 33.3 Mn in 2013 to US$ 11.4 Mn in 2015. Therefore, there is a need to develop new treatment options for SIRS. Moreover, in May 2003, Ono Pharmaceuticals Ltd. announced the termination of exclusive license agreement on Sivelestat (Elaspol 100 for Injection) with Eli Lilly and Company.

Systemic Inflammatory Response Syndrome Treatment Market: Competitive Landscape

· This report profiles the major players in the global systemic inflammatory response syndrome treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

· Prominent players operating in the global SIRS treatment market include -

o CytoSorbents Corporation

o RegeneRx Biopharmaceuticals, Inc.

o Endacea, Inc.

o Adrenomed AG

o GlaxoSmithKline plc

o Asahi Kasei Corporation

o Cardinal Health

o Smith & Nephew plc

o ConvaTec, Inc.

o AstraZeneca

o Orion Corporation

o CHIESI Farmaceutici S.p.A.

o Mylan N.V.

Systemic Inflammatory Response Syndrome Treatment Market: Key Developments

Key players in the global systemic inflammatory response syndrome treatment market are engaged in the development of new products, mergers & acquisitions, collaborations, and integration. These strategies by industry players are likely to fuel the growth of the systemic inflammatory response syndrome treatment market. Some of the growth strategies adopted by the players are:

· On March 5, 2019, CytoSorbents Corporation announced the expansion of the direct sales of CytoSorb for all applications to Poland and the Netherlands, and critical care applications to Sweden, Denmark, and Norway. Moreover, the company established CytoSorbents Poland Sp. z.o.o., a wholly-owned subsidiary of CytoSorbents Europe GmbH.

· In May 2018, approved uses of CytoSorb in the EU were expanded to include removal of bilirubin in liver disease and removal of myoglobin in trauma.

· In March 2016, CytoSorbents Corporation established CytoSorbents Switzerland GmbH, a wholly-owned subsidiary of CytoSorbents Europe GmbH, to conduct marketing and direct sales in Switzerland.

· In late June 2012, CytoSorbents Europe GmbH, a European subsidiary of CytoSorbents Corporation was established.

· In March 2011, CytoSorb, was 'CE marked' in the EU as an extracorporeal cytokine filter indicated for use in clinical situations where cytokines are elevated, allowing for commercial marketing.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Arthritis Therapeutics Market: Latest Innovations, Future Scope and Market Trends

Arthritis Therapeutics Market: Numerous Product and Novel Drug Launches Leading to New Heights

The arthritis therapeutics market, characterized by healthy growth, is witnessing numerous promising pipeline projects and new product launches in parallel to increasing awareness campaigns run by public and private organizations. The patent expiration of blockbuster drugs is putting more pressure on manufacturers to develop effective versions of these drugs, which is projected to pave the way for the advancements of biosimilar products.

According to the Centers for Disease Control and Prevention (CDC) data published in 2018, ~54 Mn adults in the U.S. have been diagnosed with arthritis, and the number will grow to ~78 Mn by 2040. In this fast-paced era, individuals can’t afford to reduce their range of motion, which pertinently entails that those residing in developed countries are massively partaking in the diagnosis and treatment of arthritis as compared to those in developing countries. In the future, as the success of health awareness campaigns increases in developing countries, manufacturers in the arthritis therapeutics market will scramble towards these countries to leverage the first mover’s advantage.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73811

Perpetual Increase in Drug Prices to Impact Health of Arthritis Therapeutics Market

Despite the stronghold of disease-modifying antirheumatic drugs (DMARDs) in the arthritis therapeutics market, next gen antibody therapeutics are found to gain ground in recent times, on account of their higher efficiency. However, the efficiency of these drugs comes at a price, indeed a high one, ranging from US$ 1,000 to US$ 3,000 per month, which could hold back the sales potential of these drugs.

The price of Humira - a default drug for the treatment of arthritis - saw a steep increase in its price by 68.7% over the last five years, which equals to US$ 3,700 for a month-long supply. Also, the wholesale cost of the drug Enbrel has risen by 80.3% in the same time period, as found by Alliance of Community Health Plans. What’s more of an adoption concern for patients is the lack of discounts and deals, and the retail price further rises when they are distributed to retailers and pharmacies. Given the recommendation for a long-term course of arthritis treatment, high cost can affect the monthly budgets of patients, which could negatively impact sales in the arthritis therapeutics market space.

Parenteral Route to Grow as Preferable Drug-consumption Mode

As per the report, in 2019, the parenteral route of drug administration is projected to be used for ~83% cases for arthritis treatment, while in the remaining ~17% cases, the oral and topical route will be preferred. To put this data into perspective, parenteral administration possesses better control over the dose and frequency, thereby ensuring an improved treatment outcome as compared to oral therapeutics. These routes of drug administration, in turn, are also found to offer better bioavailability and metabolism avoidance. On the contrary, patients are liable to maintain a course of oral drugs on their own, and in cases where they miss out on popping a pill, recovery can take a longer time.

Request for COVID19 IMPACT ANALYSIS ON Arthritis Therapeutics Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73811

Analysts’ Opinion on Arthritis Therapeutics Market

Analysts of the report opine that, the arthritis therapeutics market will record 8.5% more sales in 2019 over 2018, and continue to advance at a CAGR of ~6% during 2019-2027. The high prevalence of arthritis that primarily weakens the joints and degrades the quality of life of patients, is projected to encourage more patients to avail proper treatment options. Given the growing demand, head-to-head trails to boost the efficacy profiles of drugs intensify the competition in the arthritis therapeutics market, and strategic partnership to target new markets backed by innovative product-level approaches will form a profitable deal for manufacturers.

It is worth noting that, retail pharmacies will take over ~78% sales of these therapeutics in the year 2019, which implies the need for market players to strengthen distribution partnerships with retailers of all scales.

Global Arthritis Therapeutics Market: Overview

· The global arthritis therapeutics market was valued at ~US$ 43 Bn in 2018, and is projected to expand at a CAGR of ~6% from 2019 to 2027, to reach ~US$ 72.6 Bn by 2027.

· Increasing incidence of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and other types of arthritis across the globe, is a major factor that is likely to fuel the global arthritis therapeutics market.

· Ongoing arthritis clinical trials, increase in the geriatric population, rising investments in research & development, increasing demand for biologics, launching of novel products, and surge in mergers and strategic alliances are also anticipated to propel the growth of the global market.

· Arthritis is an inflammatory joint condition, which causes pain and stiffness, and worsens with age. More than 100 types of arthritis exists, along with different causes and underlying infections. The common types of arthritis are rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.

· Several therapeutics and medications have been developed in recent years to relieve and treat the symptoms of arthritis. The most commonly used drugs belong to the drug class of TNF inhibitors, interleukin inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and other drugs. TNF inhibitors are widely utilized for the treatment of arthritis disorders. Arthritis is a highly underdiagnosed and undertreated medical condition, with a large number of patients unsatisfied with the current treatment options available. This offers significant opportunity to biopharmaceutical players operating in the arthritis therapeutics market to offer novel drugs. The under-penetration of biologic drugs in a majority of developed and emerging markets for the treatment of arthritis offers significant opportunities to global biopharmaceutical players.

· A large number of both, small molecules and biologic products are under different phases of clinical trials. Leading companies have made significant investments in clinical R&D, and have established strategic partnerships and collaborations to accelerate new product development.

Buy Now Arthritis Therapeutics Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=73811&ltype=S

Global Arthritis Therapeutics Market: Key Segment

· Based on type, the global arthritis therapeutics market has been categorized into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and others. Among these, the rheumatoid arthritis segment is the largest, and is expected to dominate the market during the forecast period. The high market share of the rheumatoid arthritis segment can be attributed to the availability of effective biologics for its treatment. The psoriatic arthritis segment is projected to grow at the highest pace during the forecast period, due to increasing number of psoriasis patients likely to develop psoriatic arthritis.

· In terms of drug class, the global arthritis therapeutics market has been divided into TNF inhibitors, interleukin inhibitors, NSAIDs, corticosteroids, xanthine oxidase inhibitors, and others. The TNF inhibitors segment dominates the global market, owing to its higher efficacy rate as compared to other small molecules. Moreover, increasing investments toward the development of TNF inhibitor biologics are likely to drive the segment. The interleukin inhibitors segment is expected to expand at the highest CAGR, owing to ongoing clinical studies supporting their effectiveness, and quick adoption of interleukin inhibitors in gout, PsA, and RA indications.

· On the basis of route of administration, the global arthritis therapeutics market has been segmented into oral, parenteral, and topical. The parenteral segment accounted for the largest share of the global market, and is expected to continue its dominance, owing to large volume prescriptions of biologic drugs administered through intravenous and subcutaneous injections.

· Based on distribution channel, the global market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment holds a major market share, owing to the easy availability of biologics drugs in retail pharmacies, and increasing retail pharmacy stores across the globe.

Global Arthritis Therapeutics Market: Major Players

· Key players operating in the global arthritis therapeutics market include

o Novartis AG

o Eli Lilly and Company

o Amgen Inc.

o Merck & Co., Inc.

o Bristol-Myers Squibb Company

o Pfizer Inc

o Janssen Global Services

o LLC (Johnson & Johnson)

o F. Hoffmann-La Roche Ltd

o Sanofi.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Stroke Treatment Market Report Analysis With Industry Share

Oral Anticoagulants Help Minimize Risks of Internal Bleeding in Stroke Patients

Healthcare providers are recommending the consumption of non-vitamin K oral anticoagulants over commercially available medications such as Warfarin to reduce the incidence of atrial fibrillation in the stroke treatment market space. These efficacious oral anticoagulants are increasingly catching the attention of consumers and healthcare providers, as they effectively minimize the formation of clots in the blood. This is validated, as the revenue of anticoagulants amongst all drugs in the stroke treatment market is projected to hold the second-highest position, with a value of ~US$ 4.2 billion by 2027.

Oral anticoagulants are serving the convenience of stroke patients, as they can regularize any potential symptoms in home care settings. Thus, new oral anticoagulants are creating incremental opportunities for hospital, retail, and online pharmacies, as users can request for bulk orders at any given time. Healthcare companies in the stroke treatment market are developing improved formulations that make anticoagulants safer and help in reducing the risk of internal bleeding.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73917

Lucrative Opportunities in U.S. Catalyze Market Growth

Healthcare companies in the stroke treatment market should increase their focus on drug development in the U.S. Favorable guidelines by health commissions and the well-established healthcare infrastructure of the U.S. are gaining the worldwide attention of stakeholders in the stroke treatment market.

Overall, North America is anticipated to maintain its lead in terms of market share and revenue during the forecast period, with a projected value of ~US$ 6.9 billion by 2027, in the stroke treatment market. Developments in the North American healthcare landscape are creating a ripple effect in the stroke treatment landscape of the U.S.

The introduction of new guidelines by health commissions in the U.S. involves speeding up the procedure of providing thrombolytic therapy to patients suffering from acute ischemic stroke. These guidelines are increasing the convenience of patients, and healthcare providers are gaining credibility in the global stroke treatment market scenario. Healthcare providers in the U.S are aiming to increase speed targets every year. Also, patients are being provided intravenous tissue plasminogen activator (tPA) drugs within minutes of their hospital arrival.

Request for COVID19 IMPACT ANALYSIS On Stroke Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73917

tPA Drugs Reduce Ischemia Injuries and Improve Neuroplasticity

Tissue plasminogen activator (tPA) drugs accounted for the highest revenue in 2018, with a global value of ~US$ 3.4 billion in the stroke treatment market. Healthcare companies gain monopoly through the sales of tPA drugs, as these are the only therapeutic agents meant to treat patients with acute ischemic stroke that have been approved by health commissions across nations. However, delayed administration of tPA drugs in acute ischemic stroke patients can lead to health complications such as intracranial hemorrhage (ICH), hemorrhagic transformation (HT), and mortality. To overcome this challenge, companies are educating healthcare professionals regarding the administration of tPA drugs within 4.5 hours of a stroke onset. Also, manufacturers are developing new drug agents with improved formulations that help reduce the incidence of ischemia injuries in case of delayed tPA administration.

As such, healthcare companies in the stroke treatment market are increasing the availability of recombinant tissue plasminogen activators (rt-PA) to ease the health complications of acute ischemic stroke patients with their thrombolytic action. Positive clinical trials have compelled healthcare providers to prescribe rt-PA drugs in order to improve neuroplasticity in stroke patients.

Analysts’ Viewpoint

Manufacturers in the stroke treatment market are introducing reversal drug agents that minimize the incidence of life-threatening or uncontrolled bleeding in patients. Healthcare providers recommend the consumption of reversal agents in case oral anticoagulants are insufficient to treat stroke patients. Healthcare providers should increase their focus on non-pharmacological options such as percutaneous left atrial appendage occlusion for patients suffering from atrial fibrillation.

Though the market is expected to grow at a healthy CAGR of ~7%, manufacturers are challenged by the limitation of tPA drugs during delayed administration in patients. Hence, they should develop improved formulations of tPA that are efficacious, even after late administration of the drugs.

To contribute towards improving the quality of life in patients, companies should educate healthcare professionals to encourage patients for keeping a tab on weight management, as obesity leads to health complications such as sleep apnea, hypertension, hyperlipidemia, glucose intolerance, and the like.

Buy Paid Stroke Treatment Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=73917&ltype=S

Global Stroke Treatment Market: Overview

· The global stroke treatment market was valued at ~US$ 8 Bn in 2018.

· Projected to grow at a CAGR of ~7% over the forecast period, the global stroke treatment market is expected to reach a value of ~US$ 15 Bn by the year 2027.

· Rise in the prevalence of stroke across the world, surge in the elderly patient pool, and rapid rise in comorbidities such as atrial fibrillation, diabetes, and hypertension leading to high risk of developing stroke are anticipated to drive the global stroke treatment market during the forecast period.

· North America is the leading regional market in the global stroke treatment market, and will continue to have a major share throughout the forecast period of 2019 to 2027.

· The stroke treatment market in Asia Pacific is expected to expand at a high CAGR of ~8% during the forecast period.

Global Stroke Treatment Market: Key Segments

· In terms of type, the global stroke treatment market has been classified into ischemic stroke and hemorrhagic stroke. The ischemic stroke segment held a major share of the market in 2018, and the trend is anticipated to continue during the forecast period.

· Based on drug class, the global market has been segmented into tissue plasminogen activators (tPA), anticoagulants, antiplatelets, anticonvulsants, and others. The tissue plasminogen activators (tPA) segment accounted for a majority of the market share in 2018.

· In terms of distribution channel, the global stroke treatment market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a major share of the global market in 2018, and this trend is expected to continue of the period of forecast.

· The market value and forecasts for each of these segments have been provided from 2017 to 2027. The CAGRs of respective segments have also been provided from 2019 to 2027, considering 2018 as the base year.

Global Stroke Treatment Market: Regional Outlook

· In terms of region, the global stroke treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a leading share of the global market during the forecast period, owing to increase in the number of patients suffering from stroke.

· For instance, according to the American Stroke Foundation, around 795,000 people experience a new or recurrent stroke each year in the U.S., which is anticipated to boost the stroke treatment market.

· Favorable funding by governments and charitable trusts for stroke research, prevention, and treatment in the country is likely to drive the market in North America.

· The stroke treatment market in Asia Pacific is projected to grow at a rapid pace in the next few years. India and China are anticipated to be lucrative markets for stroke treatment during the forecast period, owing to the high prevalence of cerebrovascular diseases, unhealthy lifestyle choices such as smoking, poor diets, and high incidence of diabetes and hypertension, which fuel the risk of developing a stroke.

Strategic Collaborations and Innovative Product Launches to Strengthen Market Position

· In August 2017, Sanofi received FDA approval for PLAVIX (clopidogrel bisulfate), an antiplatelet medication used to reduce the risk of heart disease and stroke.

· In December 2017, Bristol-Myers Squibb Company and Pfizer Alliance, along with the National Stroke Association and iHeartMedia, launched ‘Tune in to AFib, Take Note of Stroke Risk’. This initiative aims to educate and create awareness among people living with atrial fibrillation (AFib) about the increased risk of stroke.

· In April 2016, Bristol-Myers Squibb Company entered into a collaboration with Janssen Pharmaceuticals, Inc. to develop and commercialize BMS-986177, a Factor XIa (FXIa) inhibitor. It is an anticoagulant drug indicated for the prevention and treatment of thrombotic events.

Emerging Economies to be Highly Lucrative Markets for Stroke Treatment

· Emerging economies such as India and China offer significant opportunities in the stroke treatment market.

· Rise in the prevalence and incidence of stroke in developing countries such as India and China, affecting large the elderly patient pool, offers significant opportunity to market players to exploit these untapped regions.

· Patients suffering from atrial fibrillation are at high risk of developing stroke. All these factors will provide significant opportunities to regional players in the market in the near future.

Global Stroke Treatment Market: Key Companies

· Key players in the global stroke treatment market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies

· Major companies profiled in the global market report are

o Bristol-Myers Squibb Company,

o Sanofi,

o Johnson & Johnson Services, Inc.

o Boehringer Ingelheim GmbH

o F. Hoffmann-La Roche (Genentech)

o Daiichi Sankyo Company, Limited

o Amgen Inc., AstraZeneca

o Biogen Inc.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Eye Drops and Lubricants Market Examined in New Research Report

Eye Drops and Lubricants Market: Overview

Large number of people suffer from eye problems. However, some of these may be minor and rectify on their own or could be easily treated at home. Other disorders might require a specialist’s care. Eye drops and lubricants are highly recommended in the treatment of these eye problems and are effective and less painful. Eye disorders such as soreness, diabetic macular edema, dry eye, redness, refractive errors, glaucoma, conjunctivitis, itching, CMV retinitis, and age-related macular degeneration are treated with these drops and lubricants.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=65831

Eye Drops and Lubricants Market: Key Trends

The global eye drops and lubricants market is driven by increase in incidence of ophthalmic diseases across the globe and demographic change. Additionally, drug discovery and development is projected to fuel the growth of the market during the forecast period. However, side effects associated with ophthalmic eye drops and lubricants are anticipated to restrain the market. Moreover, stringent rules & regulations are expected to hamper market growth from 2019 to 2027. However, rise in investment by key players in the eye drops and lubricants market in the emerging countries is likely to propel the market during the forecast period.

Eye Drops and Lubricants Market: Segmentation

The global eye drops and lubricants market can be segmented based on type, application, and region. In terms of type, the market can be classified into antibiotics, artificial tears, hormones, and others. Based on application, the global eye drops and lubricants market can be categorized into eye diseases, eye care, and others. The eye diseases segment can be divided into conjunctivitis, dry eye, glaucoma, refractive errors, and others.

In terms of type, the artificial tears segment is projected to account for major market share during the forecast period. This is due to increase in demand for these medications to treat artificial tears and rise in prevalence of dry eye syndrome across the world. However, the hormones segment is anticipated to expand at a high CAGR from 2019 to 2027 due to high prevalence rate of dry eye in postmenopausal women.

Based on application, the eye diseases segment held major market share in 2018 due to increase in the global geriatric population and high prevalence rate of eye diseases. However, the eye care segment is expected to expand at a high CAGR during the forecast period owing to large number of cataract and other eye-related operations that necessitate usage of eye drops.

Request for COVID19 IMPACT ANALYSIS ON Eye Drops and Lubricants Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=65831

Eye Drops and Lubricants Market: Regional Analysis

In terms of region, the global eye drops and lubricants market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to capture major market share owing to increase in health care investments by manufacturers and high R&D expenditure by companies for the development of these medications. Moreover, rise in prevalence of ophthalmic disorders fuels the growth of the market in the region. However, the market in Asia Pacific is expected to expand at a high CAGR from 2019 to 2027 due to rapid expansion of health care infrastructure, high incidence of ophthalmic diseases, and rise in health care initiatives by governments.

Pre Book Eye Drops and Lubricants Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=65831&ltype=S

Eye Drops and Lubricants Market: Competitive Landscape

Key players in the global eye drops and lubricants market include Novartis International AG (Alcon Inc.), Akorn Consumer Health (TheraTears), Allergan plc, ROHTO Pharmaceutical Co., Ltd., Johnson & Johnson, Pfizer, Inc., Similasan Corporation USA, Sager Pharma Kft., Prestige Consumer Healthcare, Inc., and Valeant pharmaceuticals International, Inc. (Bausch & Lomb Incorporated).

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

· Customer Experience Maps

· Insights and Tools based on data-driven research

· Actionable Results to meet all the business priorities

· Strategic Frameworks to boost the growth journey

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Exosome Technologies Market Examined in New Research Report

Exosome Technologies Market: Overview

Exosomes are extracellular vehicles produced by most of the cells. These are present in various body fluids and usually contain RNA and specific set of proteins. Exosomes play an important role intercellular communication. These can transfer molecules from one cell to another. Exosomes are being tested for therapeutic applications such as biomarkers, drug delivery systems, and therapies for diseases such as cancer and cardiovascular diseases. An article published by NCBI stated that exosomes have immunotherapeutic applications or can act as a drug delivery system for targeted therapies with drugs and biomolecules. This is due to their ability to selectively express proteins. Additionally, various studies have shown the potential applications of exosomes in drug and nucleic acid delivery, biomarkers, and anticancer vaccines.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=65840

Exosome Technologies Market: Key Trends

Increase in awareness about exosome technologies, rise in prevalence of chronic disorders such as cancer and cardiovascular diseases, improved health care infrastructure, rise in R&D spending, technological advancements, surge in investment by major players in the development of treatments, rich product pipeline, and increase in government initiatives are the major drivers of the global exosome technologies market. However, lack of skilled professionals and stringent regulatory procedures are projected to act as major restraints of the global market.

Exosome Technologies Market: Segmentation

The global exosome technologies market can be segmented based on biomolecule type, application, end-user, and region. In terms of biomolecule type, the global market can be classified into non-coding RNAs, mRNA, proteins / peptides, DNA fragments, and lipids. The non-coding RNAs segment dominated the market in 2018, and the trend is projected to continue during the forecast period. Growth of the segment is attributed to wide use of RNAs in the development for therapeutics and diagnostics for various diseases. Based on application, the global exosome technologies market can be divided into drug discovery, drug delivery, oncology, neurodegenerative diseases, cardiovascular diseases, infectious diseases, and others. The drug delivery segment dominated the market in 2018 and is expected to continue its dominance during the forecast period. This is attributed to increase in research initiatives for the development of exosome as drug delivery system. An article published by NCBI indicated that exosomes have shown significant potential in the delivery of drugs or biomolecules in cell therapy treatments. In terms of end-user, the global market can be categorized into health care providers, pharmaceutical & biotechnology companies, and others. The pharmaceutical & biotechnology companies segment dominated the market in 2018 due to high preference for this channel of distribution. The segment is likely to sustain its leadership position from 2019 to 2027.

Request for COVID19 IMPACT ANALYSIS ON Exosome Technologies Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=65840

Exosome Technologies Market: Regional Analysis

In terms of region, the global exosome technologies market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2018 and is projected to constitute significant market share during the forecast period. The market in the region is anticipated to grow at a rapid pace due to increase in geriatric population, rise in prevalence of chronic diseases such as cancer and cardiovascular diseases, technological advancements, and surge in acceptance of these technologies in the region. The market in Asia Pacific is expected to expand at a high CAGR in the next few years, driven by technological advancements, increase in research spending, and improvement in health care infrastructure in developing countries.

Pre Book Exosome Technologies Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=65840&ltype=S

Exosome Technologies Market: Competitive Landscape

Major players operating in the global exosome technologies market include Thermo Fisher Scientific, Inc., Danaher, Fujifilm, Lonza, Illumina, Inc., Qiagen, Takara Bio Company, Exocome Diagnostics, and ExoCan Healthcare Technologies Pvt. Ltd.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

· Customer Experience Maps

· Insights and Tools based on data-driven research

· Actionable Results to meet all the business priorities

· Strategic Frameworks to boost the growth journey

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Antinuclear Antibody Test Market is Booming Worldwide Scrutinized in New Research

Antinuclear Antibody Test Market: Overview

Antinuclear antibodies are a group of autoantibodies produced by an individual’s immune system when it fails to distinguish between self and foreign particles. Antinuclear antibody (ANA) is also known as fluorescent antinuclear antibody (FANA) and antinuclear antibody screen. Antinuclear antibodies attack body’s own cells. Hence, these are called antinuclear, as these target the nucleus of cells. Antinuclear antibodies react with components of the body’s own healthy cells and cause symptoms and signs such as organ & tissue inflammation, muscle & joint pain, and fatigue. Antinuclear antibodies test detects autoantibodies in the blood. An antinuclear antibodies test determines the presence of antinuclear antibodies in the blood. If a test detects antinuclear antibodies in the body of an individual, it could mean that the person has an autoimmune disorder. An antinuclear antibodies test is used to help diagnose autoimmune disorders, including rheumatoid arthritis, scleroderma, Sjogren's syndrome (a rare disease condition that affects the body’s moisture-making glands), and systemic lupus erythematosus (the most common type of lupus, a chronic condition affecting multiple parts of the body including kidneys, blood vessels, brain, and joints).

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17930

Antinuclear Antibody Test Market: Key Trends

The global antinuclear antibody test market is projected to grow at a rapid pace during the forecast period. Rise in prevalence of autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus and increase in adoption of antinuclear antibodies tests are the major factors anticipated to drive the global market during the forecast period. According to the Lupus Foundation of America, about 5 million people across the globe and an estimated 1.5 million people in the U.S. are suffering from lupus. Based on an estimation, the incidence rate of lupus is 16,000 new cases per year. Lupus affects mostly women of childbearing age. However, children, teenagers, and men develop lupus too. Most of the people suffering from lupus develop the disease between ages 15 and 44. According to the Arthritis Foundation, about 1 in 3 people aged between 18 and 64 have arthritis. The number of adults in the U.S. with doctor-diagnosed arthritis is estimated to rise by 49% to reach 78.4 million (25.9% of all adults) by 2040.

Request for COVID19 IMPACT ANALYSIS ON Antinuclear Antibody Test Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=17930

Antinuclear Antibody Test Market: Segmentation

The global antinuclear antibody test market can be segmented based on product, application, technique, and region. In terms of product, the market can be classified into reagents & assay kits, systems, and software & services. The reagents & assay kits segment is projected to account for the largest market share during the forecast period. This is due to high adoption of reagents and assay kits in research and clinic settings. Based on application, the global antinuclear antibody test market can be categorized into systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren’s syndrome, and others. In terms of technique, the market can be divided into immunofluorescence assay, multiplex assay, and enzyme-linked immunosorbent assay (ELISA). The ELISA segment is anticipated to grow at a rapid pace during the forecast period due to ease of use and moderate level of operator skills required to perform the test.

Pre Book Antinuclear Antibody Test Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=17930&ltype=S

Antinuclear Antibody Test Market: Regional Analysis

Based on region, the global antinuclear antibody test market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is projected to lead the global market during the forecast period, followed by Europe. Dominance of the two regions is attributed to high patient awareness, better health care infrastructure, and presence of advanced tests. Asia Pacific is expected to be the fastest growing market during the forecast period due to high prevalence of autoimmune diseases in countries such as India and China.

Antinuclear Antibody Test Market: Competitive Landscape

Key players operating in the global antinuclear antibody test market include Bio-Rad Laboratories, Alere, Inc., Antibodies, Inc., ZEUS Scientific, Erba Diagnostics, Immuno Concepts, Inova Diagnostics, Trinity Biotech plc, and Euroimmun AG.

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

mohitt · 5 years ago

Text

Rubber Gloves Market is Booming Worldwide Scrutinized in New Research

Rubber Gloves Market: Overview

Rubber gloves are made out of rubber obtained from natural source. Gloves are disposable items used during medical examinations and procedures intended to prevent cross-contamination between health care providers and patients. Examination gloves are available in sizes XS, S, M, and L. Some brands also offer size XL. Gloves are primarily used by health care professionals, generally for examination and surgery. Surgical gloves are sized more specifically, as these are worn for a much longer period of time and require excellent dexterity. There are various benefits of rubber gloves such as proper fit, good touch sensitivity, cost-effectiveness, can be worn for an extended period of time, elastic & strong, and biodegradable.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=65864

Rubber Gloves Market: Key Trends

The global rubber gloves market is driven by rise in awareness about hygiene and safety among health care professionals and patients. Rubber gloves are used in various industries such as pharmaceutical, health care, food, biotechnology, automobile, and others. Rubber gloves provide safety from reactive materials, toxic chemicals, and unhygienic conditions. Additionally, manufacture of specific products such as medical device, drugs, and foods, which involve high level of hygiene and handling, is a crucial process that could cause product contamination if proper care is not taken. Demand for rubber gloves is anticipated to increase in the near future owing to the requirement of workers’ safety, product quality control, hygiene, and protection against chemicals. Moreover, usage of rubber gloves is rising among doctors, health care professionals, and surgeons to avoid infections and other complications. Furthermore, rubber gloves have application in household use such as washing and cleaning. Hence, rise in concerns about hygiene, product quality, and safety is projected to boost the growth of the market in the near future.

Request for COVID19 IMPACT ANALYSIS ON Rubber Gloves Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=65864

Rubber Gloves Market: Segmentation

The global rubber gloves market can be segmented based on product type, sterilization type, application, and region. In terms of product type, the market can be bifurcated into powdered gloves and non-powdered gloves. Non-powdered gloves have more applications in surgeries and other sensitive procedures. In terms of sterilization type, the global rubber gloves market can be classified into sterile gloves and non-sterile gloves. Sterile gloves are likely to witness higher demand during the forecast period due to rise in preference of health care providers to use sterile gloves to avoid contamination. Based on application, the market can be categorized into medical use and non-medical use. The medical use segment is likely to account for major share of the market during the forecast period.

Pre Book Rubber Gloves Market

https://www.transparencymarketresearch.com/checkout.php?rep_id=65864&ltype=S

Rubber Gloves Market: Regional Analysis

Geographically, the global rubber gloves market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was the leading market for rubber gloves in terms of revenue in 2017 owing to rise in prevalence of various diseases and increase in demand for sterile gloves. The market in North America is projected to expand at a high CAGR during the forecast period. The market in Asia Pacific, Latin America, and Middle East & Africa is anticipated to witness strong growth from 2019 to 2027 due to increase in patient population and growing health care industry. The rubber gloves market in developing countries such as Brazil, China, and India is expected to witness robust growth between 2019 and 2027, due to rise in investments by governments of these countries to improve health care facilities.

Rubber Gloves Market: Competitive Landscape

Key players operating in the global rubber gloves market include Ansell Healthcare, Hartalega Holdings Berhad, Cardinal Health, Top Glove Corporation Bhd, Kossan Rubber Industries Bhd, Supermax Corporation Berhad, Clean Q Grip, MREPC MARKETPLACE, SHIELD Scientific, Rubberex, UG Healthcare, and Valutek.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

· Customer Experience Maps

· Insights and Tools based on data-driven research

· Actionable Results to meet all the business priorities

· Strategic Frameworks to boost the growth journey

About us

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes